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Background: The results of surgery for recurrent colorectal liver metastases (CLM) after radiofrequency
ablation (RFA) have not been evaluated.
Methods: From 1993 to 2009, data on patients who underwent resection or RFA for recurrent CLM
were collected prospectively. Inclusion criteria for this study were RFA as initial treatment for CLM and
resection of recurrent CLM after RFA. Postoperative results and oncological outcomes were analysed.
Results: Twenty-eight patients (median number of tumours 1 (1–3), median size 2·8 (2·0–4·0) cm)
met the inclusion criteria. Of these, 22 had recurrence at the site of RFA only, two developed new
lesions, whereas four had both recurrent and de novo metastases. At the time of resection, patients had a
median of 1 (1–13) CLM with a median maximum tumour diameter of 5·0 (1·8–11·0) cm, significantly
larger than at the time of RFA (P = 0·021). Ninety-day postoperative morbidity and mortality rates
were 46 per cent (13 of 28) and 7 per cent (2 of 28) respectively. After a median follow-up of 35 (0–70)
months, 3-year overall and disease-free survival rates calculated by Kaplan–Meier analysis were 60 and
29 per cent respectively. Plasma carcinoembryonic antigen level over 5 ng/ml at the time of resection
and a rectal primary tumour were associated with worse survival (P = 0·041 and P = 0·021 respectively).
Conclusion: Resection for recurrence after RFA is associated with significant morbidity and modest
long-term benefit.
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Introduction
Although radiofrequency ablation (RFA) has not been
evaluated formally as an alternative to liver resection
in patients with resectable colorectal liver metastases
(CLM)1–3, it is increasingly being used for this indication4.
However, RFA is associated with an increased risk of local
recurrence, which frequently includes regrowth of the
ablated tumour5,6. The survival impact is controversial;
overall survival of patients who develop recurrence after
RFA for CLM appears to be shorter than in patients
with recurrence after resection of CLM6–10. Repeat
hepatectomy in the event of recurrence after resection for
CLM is well established11–15. Hepatectomy is proposed
for selected patients with recurrent CLM after RFA,
but the feasibility and results of this approach have
not been evaluated. The aim of this study was to
assess the clinicopathological characteristics, perioperative
results and oncological outcomes of patients undergoing
hepatectomy for recurrent CLM after RFA.
Methods
Between December 1993 and December 2009, data on
115 consecutive patients who underwent a laparotomy for
recurrent CLM after RFA or resection at the University
of Texas M. D. Anderson Cancer Center were collected
prospectively. The study was approved by the Institutional
Review Board of M. D. Anderson Cancer Center.
Diagnosis of recurrent metastases
and preoperative assessment
The diagnosis of recurrent CLM was made using helical
computed tomography (CT) with a liver protocol (rapid
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injection of 150 ml intravenous contrast material with
image reconstruction of 2·5–5 mm through the liver) or
magnetic resonance imaging16,17. Recurrent CLM were
deﬁned as local recurrence when they were observed
at the site of previous RFA18. Other recurrent CLM
were deﬁned as new lesions (Fig. 1)17–19. Beginning in
1998, 9-ﬂuorodeoxyglucose positron emission tomography
(FDG-PET) was used in some patients with uncertain
ﬁndings of recurrence, or to rule out extrahepatic disease
(Fig. 1)20. When recurrence of CLM was suspected but
not conﬁrmed after the initial imaging, a new evaluation
including CT and FDG-PET was generally repeated
approximately 1 month later to detect additional changes.
When the diagnosis of recurrence was conﬁrmed, the
patient’s performance status was carefully evaluated. In
most patients, the decision to operate for recurrent
CLM was made during a multidisciplinary meeting
including hepatobiliary surgeons, imaging radiologists,
interventional radiologists and medical oncologists. Final
pathology conﬁrmed recurrence of cancer in all patients.
Surgical procedure
Liver resection was performed with curative intent only if it
was believed that all tumour deposits could be completely
resected. During laparotomy, the peritoneal cavity was
inspected to rule out extrahepatic disease. Palpation and
intraoperative ultrasonography were carried out in all
patients to deﬁne better the location of themetastases in the
liver, and their relationship with portal pedicles and hepatic
veins. When dense adhesion of recurrent CLM to an
adjacent organ was found, en bloc resection was undertaken
to avoid peritoneal dissemination of disease. Parenchymal
transection was performed using an ultrasonic dissector,
and haemostasis was achieved by means of saline-linked
cautery as described previously21,22. Major hepatectomy
was deﬁned as liver resection including three or more
contiguous liver segments.
The number and size (diameter of the largest metastasis)
of CLM were evaluated on resected specimens in all
patients; in those who had previously undergone RFA,
the size of the scar was excluded from the size of the
metastasis. The margin width was deﬁned as the distance
between tumour and the closest inked section23.
Postoperative and long-term outcomes
Postoperative morbidity, 30-day mortality and 90-day
mortality rates were evaluated. Major postoperative com-
plications were deﬁned as complications of grade 3 or
higher (necessitating a surgical, endoscopic or radio-
a  CT before RFA
b  CT 1 month after RFA
c  PET–CT 6 months after RFA
Fig. 1 Single segment VI colorectal liver metastasis on computed
tomography (CT) a before radiofrequency ablation (RFA) and
b 1 month after RFA. Positron emission tomography
(PET)–CT 6 months after RFA showing local recurrence
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logical procedure) in the Dindo classiﬁcation24. Post-
operative liver insufﬁciency was deﬁned as a postoper-
ative bilirubin peak level of at least 7 mg/dl25. Overall
survival was calculated from the time of hepatectomy
for recurrent CLM. After hepatectomy, the need for
postoperative chemotherapy was discussed between oncol-
ogists and surgeons at a multidisciplinary meeting; factors
taken into account included the completeness of resec-
tion, the extent and toxicity of previous chemother-
apy, and the macroscopic and microscopic response
to it26,27.
Statistical analysis
Continuous data were expressed as mean(s.d.) and median
(range). Comparisons between groups were made using the
Mann–Whitney U test for continuous variables, and χ2
or Fisher’s exact test for proportions. Overall and disease-
free survival were calculated from the date of resection
of recurrent CLM using the Kaplan–Meier method, and
compared using the log rank test. Univariable analysis
was used to examine the relationship between survival in
patients who underwent resection of recurrent CLM after
RFA and the following variables: location of the primary
tumour, lymph node status at the time of diagnosis of the
primary tumour, synchronous CLM (versus metachronous;
synchronous metastases were deﬁned as liver metastases
diagnosed at the same time or within 6 months after
diagnosis of the primary colorectal cancer), number of
initial CLM (single or multiple), initial size of CLM
(less than 3 cm versus 3 cm or more), time to recurrence
(12 months or more versus less than 12 months), plasma
level of carcinoembryonic antigen (CEA) at the time of
resection of recurrent CLM (5 ng/ml or less versus more
than 5 ng/ml), local recurrence alone (versus new lesions
with or without local recurrence), number of recurrent
CLM (single or multiple), size of recurrent CLM (less
than 3 cm versus 3 cm or more), extension of CLM
to an adjacent organ, preoperative chemotherapy before
resection of recurrent CLM, positive surgical margin
at the time of resection of recurrent CLM, need for
transfusion during surgery for recurrence, occurrence
of major postoperative complications, and postoperative
chemotherapy. All variables associated with survival with
P ≤ 0·20 in the univariable proportional hazard model
were subsequently entered into a Cox multivariable
regression model with backward elimination. P < 0·050
was considered statistically signiﬁcant. Statistical analysis
was performed using SPSS version 17.2 (SPSS, Chicago,
Illinois, USA).
Results
Clinicopathological features
BetweenDecember 1993 andDecember 2009, 115 patients
underwent a laparotomy for recurrent CLM. Procedures
performed are listed in Table 1. Clinicopathological
features of the 28 patients who underwent hepatectomy
for recurrent CLM after RFA are summarized in
Table 2.
At the time of ﬁrst treatment of CLM, six of 28 patients
underwent RFA for multiple CLM, whereas 22 underwent
RFA for a solitarymetastasis. CLM subsequently presented
as local recurrence in 22 patients, local recurrence
associated with new lesions in four and new lesions
alone in two patients. The majority of patients (20 of
28) underwent RFA as ﬁrst treatment in the pre-referral
setting and were seen at this institution at the time of
recurrence. The median time from the initial treatment
to recurrence was 12 (2–147) months. Recurrent CLM
were signiﬁcantly larger than those treated initially (5·0
(1·8–11·0) versus 2·8 (2·0–4·0) cm; P = 0·021), but the
median number of lesions was similar (1 (1–13) versus 1
(1–3); P = 0·340). Fourteen patients had FDG-PET at
the time of diagnosis of recurrent CLM. Decision-making
regarding resection of recurrent CLM was undertaken
formally at a multidisciplinary meeting in 23 of 28
patients.
Perioperative results and oncological outcome
Operative details and postoperative complications are sum-
marized in Table 2. Among 12 patients who underwent
resection of adjacent organs, 11 had en bloc diaphrag-
matic resection, and in two of these the diaphragmatic
resection was combined with resection of the peri-
cardium (1) or lung wedge en bloc resection (1). Seven
patients developed major complications. Two patients
died during surgery when attempts to mobilize the
right liver surrounding the ablation cavity led to vena
Table 1 Procedures used in 115 patients who underwent
laparotomy for recurrent colorectal liver metastases
No. of patients
(n = 115)
Resection after RFA 28 (24·3)
Resection after resection 43 (37·4)
Resection after resection + RFA 32 (27·8)
Resection + RFA after resection 8 (7·0)
RFA after resection 4 (3·3)
Values in parentheses are percentages. RFA, radiofrequency ablation.
 2011 British Journal of Surgery Society Ltd www.bjs.co.uk British Journal of Surgery 2011; 98: 1003–1009
Published by John Wiley & Sons Ltd
1006 A. Brouquet, J.-N. Vauthey, B. D. Badgwell, E. M. Loyer, H. Kaur, S. A. Curley and E. K. Abdalla
Table 2 Comparison of clinicopathological features and outcomes
of patients who underwent hepatectomy for recurrent colorectal
liver metastases after radiofrequency ablation
No. of patients
(n = 28)
Initial diagnosis of CLM
Age (years)* 61 (35–80)
Sex ratio (M : F) 20 : 8
Body mass index (kg/m2)† 29(7)
Rectal primary tumour 7
Node-positive primary tumour 20
Liver metastases
Synchronous 12
No. of liver deposits* 1 (1–3)
Maximum tumour diameter (cm)* 2·8 (2·0–4·0)
Treatment of metastases
Percutaneous RFA 14
Intraoperative RFA 14
Recurrence of CLM
Time to recurrence (months)† 16(12)
Liver metastases
No. of liver deposits* 1 (1–13)
Maximum tumour diameter (cm)* 5·0 (1·8–11·0)
New lesions 2
Local recurrence ± new lesions 26
Preoperative chemotherapy before liver surgery 12
Type of resection
Major liver resection (≥ 3 liver segments) 19
Resection of adjacent organ(s) 12
Positive surgical margin 9
Pringle manoeuvre 13
Estimated blood loss (ml)* 725 (50–10 000)
Blood transfusion 9
Duration of operation (min)* 203 (82–447)
Postoperative death 2
Postoperative morbidity 13
Bleeding 2
Intra-abdominal collection 3
Liver insufficiency 1
Pleuropulmonary complication 2
Major complication‡ 7
Length of hospital stay (days)* 7 (4–12)
Values parentheses are percentages unless indicated otherwise; *values are
median (range) and †mean(s.d.). ‡Requiring surgical, endoscopic or
radiographic intervention. CLM, colorectal liver metastases; RFA,
radiofrequency ablation.
cava and hepatic vein injury. This led to a change
in operative technique for tumours in this location;
the anterior approach with hanging manoeuvre was
used subsequently, eliminating the possibility of this
complication28,29. Three patients developed an intra-
abdominal collection requiring radiological percutaneous
drainage, and two developed a pleural effusion requiring
chest drainage.
The median follow-up for the entire population was 35
(0–70) months from the date of resection of recurrent
CLM. Median overall survival was 47 (95 per cent
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Fig. 2 Overall and disease-free survival in patients who had
hepatectomy for recurrent colorectal liver metastases after
radiofrequency ablation
Table 3 Univariable and multivariable analysis of factors
associated with survival in patients who underwent hepatectomy
for recurrent colorectal liver metastases after radiofrequency
ablation
Univariable
P*
Multivariable
P†
Initial diagnosis of CLM
Rectal primary tumour 0·021 0·231
Nodal metastases 0·514
Liver metastases
Synchronous 0·448
Multiple 0·179 0·324
Maximum tumour diameter 0·752
≥ 3 cm
Recurrence of CLM
Time to recurrence < 12 months 0·779
Local recurrence only 0·421
Preoperative chemotherapy before 0·279
liver surgery
Plasma CEA level > 5 ng/ml 0·041 0·421
Liver metastases
Multiple 0·476
Maximum tumour diameter 0·506
≥ 3 cm
Tumour extension to adjacent 0·481
organs
Blood transfusion 0·887
Major postoperative complication 0·846
Positive surgical margin 0·659
Postoperative chemotherapy 0·212
CLM, colorectal liver metastases; CEA, carcinoembryonic antigen.
*Proportional hazard model; †Cox regression model.
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conﬁdence interval 27 to 67) months. One- and 3-year
overall survival rates following resection of recurrent CLM
after RFA were 85 and 60 per cent respectively (Fig. 2).
Eighteen patients developed a further recurrence following
hepatectomy for recurrent CLM after RFA; 1- and 3-
year disease-free survival rates after resection were 65 and
29 per cent respectively (Fig. 2). Among the 18 patients
who developed a second recurrence after hepatectomy
for recurrent CLM, ﬁve had liver-only recurrence, 11 had
extrahepatic recurrence, and two had liver and extrahepatic
recurrence.
Predictors of survival
Univariable analysis showed that rectal location of the
primary tumour and plasma CEA level over 5 ng/ml
at the time of resection of recurrent CLM were
associated with worse survival in patients undergoing
resection of recurrent CLM (Table 3). Neither of these
factors remained signiﬁcant in multivariable analysis.
Discussion
This study has shown that hepatectomy for recurrent
CLM in patients initially treated with RFA is feasible
but complex, and associated with signiﬁcant morbidity.
Hepatectomy for recurrent CLM after RFA can be
associated with prolonged survival, but the chance of
deﬁnitive cure of metastatic disease in this context is
low. In contrast, repeat hepatectomy for recurrent CLM
after resection is generally associated with good long-
term outcome, with 5-year survival rates ranging from 41
to 88 per cent11,12,14. The excellent outcome for patients
with recurrence after initial resection is attributed to
the ‘biological’ selection of patients with oncologically
favourable tumours, for example those with oligonodular
recurrence11,30. Unfortunately, despite using the same
criteria for resection of recurrent CLM after RFA, only a
small minority of patients experienced prolonged disease-
free survival.
The concept that incomplete treatment may create
a microenvironment that promotes tumour growth is
supported by the present study, based on the ﬁnding
of larger recurrent tumour compared with initial ablated
lesion and regrowth of tumour surrounding the RFA
cavity17,18. Careful review of the imaging demonstrates
recurrence with acceptable accuracy, and complete
treatment with ablation is typically associated with a stable
or collapsing ablation cavity, not increase in size of the
ablation zone. Evaluation of the completeness of ablation
on early postprocedure imaging may help to predict
recurrence and to tailor imaging follow-up in high-risk
patients.
The present ﬁndings heighten the concern surrounding
calls to use RFA as an alternative to resection for
CLM in a fashion analogous to RFA for hepatocellular
carcinoma in cirrhosis, where RFA use may be better
supported by outcome data31. Poor overall and disease-
free survival rates in this study, despite salvage resection,
and the markedly inferior outcome of RFA compared
with resection for solitary CLM6, further undermine any
proposal for a randomized trial comparing RFA and
resection for CLM2,9. The statement that the mode of
initial local treatment (RFA rather than resection) may
not affect overall survival of patients with potentially
curable CLM is further suspect given results of a recent
study conﬁrming an increased local recurrence rate and a
shorter time to progression when RFA was compared with
resection as a treatment for CLM9. Strong evidence from
previous studies has demonstrated that local recurrence
rates are higher and survival is shorter in patients treated
with RFA for initial CLM than in patients treated with
liver resection1,3,5,6. The present series included only
patients who had resectable recurrence after RFA. The
total number of patients with recurrence after RFA could
not be determined because this study included patients
who underwent ablation before referral to this institution.
The present study has shown that resection for recurrent
CLM after initial treatment with RFA can be complex,
and associated with a signiﬁcant risk of intraoperative
difﬁculties and postoperative complications. The frequent
need for resection of structures adherent to the liver as
a result of previous ablation, and the risk of bleeding
related to reoperative surgery12 and to the friable nature
of the hepatic parenchyma and vessels near the ablation
zone (mean estimated blood loss over 500 ml), probably
contribute to the morbidity associated with this type of
surgery. Use of techniques such as the anterior approach to
right-sided tumours has enabled avoidance of the problems
of cracking of the liver and hepatic veins associated with
liver mobilization after ablation28,29. Regardless of the
presence of actual tumour invasion, en bloc resection of
adherent diaphragm is often required to facilitate safe
resection because of the loss of normal tissue planes
between the liver and adjacent structures.
In the present series, rectal primary tumour and
preoperative plasma CEA level were associated with
outcome after resection of recurrent CLM following RFA.
These factors were not independent predictors of survival
probably owing to the limited sample size. Neither the
characteristics of CLM at the time of presentation nor
at the time to recurrence had a signiﬁcant impact on
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survival, underscoring the concept that the number or
size of recurrent CLM should not deﬁne indications or
contraindications for surgery. The potential to remove all
tumour deposits while preserving an adequate remnant
liver, combined with assessment of patient performance
status, is more likely to guide the appropriate selection of
candidates for demanding surgery of this type.
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Snapshot Quiz 11/06
Question: This CT scan shows the cause of duodenal obstruction in a 78-year-old patient.
The operative photograph shows the cause being removed. What is the diagnosis?
The answer to the above question is found at the end of the Your Views section in this issue
of the BJS.
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